#### International Experience: Real World Case of Innovative Pharmaceuticals/HTA Applications In Selected Countries

Qiang Shi, MD, PhD Oct 21, 2017

## Outline

- o HTA system overview (TW, SK, AUS)
- HTA dossier overview
- o Study Examples
- Value of RWE

### Objective


 To build on concepts learned and understanding of the use of data and information beyond the HTA dossier



Evidence may be necessary, but it is certainly not sufficient. The findings of research need to be translated into information that is useful for each health care decision maker.



#### Taiwan HTA: Two Steps Decision Making Process



### Taiwan hta: Pricing Policy/Price Premium

Category	Definition	Pricing formula	
1	Major improvement in efficacy as shown in head-to-head comparison or indirect comparison with the most commonly used treatment	A10 median	
2A	A new drug with moderate improvement in clinical efficacy compared with the most commonly used treatment	(capped at A10 median) A10 lowest International price comparison	
2B	The clinical efficacy of the new drug is similar to that of an NHI-listed drug	Treatment course comparison Price in country manufactured	

#### **Price Premium:**

- •10% mark-up with local R&D and clinical trials reaching up to a certain scale
- •Up to 10% mark-up with local pharrmaco-economics research
- •Up to 15% mark-up of superior safety than the comparator
- •Up to 15% mark-up of superior efficacy than the comparator
- •Up to 15% mark-up of more convenient (kit) than the comparator

### South Korea: HTA System Overview

#### Positive List System (PLS)

- Introduced in 2007 as a part of the DERP (Drug Expenditure Rationalization Plan)
- Listing of drugs with higher therapeutic & economic value by using cost-effectiveness analysis

#### • Pricing and Reimbursement Decision Making Process


- Two Step Process: HTA Process (HIRA, HTA Agency)→ Price Negotiation (NHIS, Payer)




NHIS (National Health Insurance Service) MoHW (Ministry of Health and Welfare)

- HIRA Evaluation Result
- NHIS Negotiation Result

# South Korea: Decision Making Process



### Australia reimbursement process



# Taiwan: HTA Reports will be on the web before PBRS meeting

HTA report is one of the reference to help Expert members to make **recommendation** toward the new drug, and **how many % of PE study mark up** should be.

#### **HTA Report includes:**

- 1. Disease/Products Overview
- 2. Relative effectiveness
- 3. Economic evaluation
- 4. Cost-Effectiveness
- 5. Budget Impact Analysis

	104CDR03011_edarbyclor Tablet 40mg/12.5mg没40mg/25mg
	財團法人醫藥品查驗中心
	醫療科技評估報告補充資料
商	品名: edarbyclor Tablet 40mg/12.5mg 及 40mg/25mg
學	名:azilsartan medoxomil/chlorthalidone 40mg/12.5mg 及 40mg/25mg
事	由:台灣武田藥品工業股份有限公司向衛福部健保署提出 edarbyclor tablet
401	ng/12.5 mg 及 40 mg/25 mg 等 2項新療效複方藥品項納入健保給付之建議,因其
给	计建議書中包含國內實施藥物經濟學研究資料,健保署遂委請查驗中心就國內藥
物	經濟學研究部份進行品質評估。
完	或時間:民國 104 年 4 月 21 日
aL.	体
1.	估結論 建議者所通送的國內經濟學研究結果顯示,AZL-M/CLD 40 mg/12.5 mg及 AZL-M/CLD 40 mg/25 mg與Valsartan/HCT 320 mg/12.5 mg比較的ICER值分別為 108萬/QALY及114萬/QALY。
1.	建議者所遞送的國內經濟學研究結果顯示, AZL-M/CLD 40 mg/12.5 mg及 AZL-M/CLD 40 mg/25 mg與Valsartan/HCT 320 mg/12.5 mg比較的ICER值分別者 108萬/QALY及114萬/QALY。
	建議者所遞送的國內經濟學研究結果顯示, AZL-M/CLD 40 mg/12.5 mg及 AZL-M/CLD 40 mg/25 mg與Valsartan/HCT 320 mg/12.5 mg比較的ICER值分別為 108萬/QALY及114萬/QALY。 2. 查驗中心認為建議者採用的模型結構清楚,且在病人危險因子分布及併發系
555	建議者所遞送的國內經濟學研究結果顯示,AZL-M/CLD 40 mg/12.5 mg及 AZL-M/CLD 40 mg/25 mg與Valsartan/HCT 320 mg/12.5 mg比較的ICER值分別書 108萬/QALY及114萬/QALY。 2. 查驗中心認為建議者採用的模型結構清楚,且在病人危險因子分布及併發系 成本部份參數採用適當的本土參數,但因愛限療效參數未採用本品與各藥品間
	建議者所遞送的國內經濟學研究結果顯示, AZL-M/CLD 40 mg/12.5 mg及 AZL-M/CLD 40 mg/25 mg與Valsartan/HCT 320 mg/12.5 mg比較的ICER值分別者 108萬/QALY及114萬/QALY。

#### South Korea: HTA Dossier And Process Overview

#### HIRA (Health Insurance Review Agency)

- Label: Efficacy & Safety
- Clinical Usefulness
- Economic Model
- Reimbursement Status in Other Countries
- Global Treatment Guideline
- Budget Impact
  - Epidemiology
  - Alternatives
  - Estimated Sales

#### Reimbursement Decision (by DREC\*)

### NHIS (National Health Insurance Service) HTA Price (DREC Result) Total Cost of Alternative

- Total Cost of Alternative
   Treatment
- Reference Price ➤ OECD Countries + Taiwan & Singapore
- Price Ratio (Relative Price)
- Actual R&D Cost (Local Only)
- Listed in less than 3 Countries: below 80% of Alternative Treatment or Relative Price

**Price & Volume Negotiation** 


#### MoHW (Ministry of Health and Welfare)

- HIRA Evaluation Result
- NHIS Negotiation Result

**Final Decision** 

### **AUSTRALIA-PBAC** major submission


#### Submission structure for a major submission



Source: Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee <a href="http://www.pbac.pbs.gov.au/">http://www.pbac.pbs.gov.au/</a>

### Taiwan Rheumatoid Arthritis Treatment Pattern Study

• **Objectives:** The objective of this study was to use the NHIRD to estimate the percentage of newly treated patients with inadequate response (IR) to biologic disease-modifying antirheumatic drugs (bDMARDs) as well as the costs and resources.



### South Korea Rheumatoid Arthritis Treatment Pattern Study

 To characterize real-world patients, treatment patterns and costs among RA patients in South Korea receiving a bDMARD or tofacitinib since the major reimbursement guideline changes introduced in 2013.




Figure 1a. Index bDMARD/tofacitinib for all patients

Tofacitinib was only reimbursed in South Korea at the end of the study period, hence the low number of patients observed that were prescribed tofacitinib.

#### Table 1. Annual all-cause/RA-related per-patient costs for initiators, switchers and overall

Per-patient costs (All-cause / RA-related), mean [€]	Initiators (n=2,173)	Switchers (n=662)	<b>Total</b> (n=2,835)
Total direct costs	8,327 / 7,368	8,662 / 7,567	8,405 / 7,414
Hospitalizations	1,226 / 721	1,523 / 880	1,295 / 758
Joint replacements	164 / 98	164 / 138	164 / 108
Outpatient attendances	328 / 145	325 / 143	328 / 145
bDMARD infusions	10 / 10	14 / 14	11 / 11
bDMARD subcutaneous injections	4 / 4	1 / 1	3/3
Serious infections	405 / 258	430 / 323	411 / 273
Monitoring	183 / 166	207 / 182	188 / 170

A conversion rate of ₩1=€0.00078 was used.

# Stakeholder requirements in EU: HTA vs. Regulatory


Regulatory*	HTA** Burden of target disease (mortality, morbidity	
Exposure		
Epidemiology of the indication(s)	prevalence, incidence, DALYs, QALYs)	
Prescribing conditions	Conditions of use	
	Expected benefit of the technology	
Characteristics of patients who actually	- On burden of disease	
receive the drug	- On management of disease	
	- Economical	
New safety concerns, known ones, risk	- Organisational	
factors	- Social	
Efficacy in real life / in specific populations	Confirmation of the expected benefit	
Effectiveness of risk minimization measures	Potential to cover unmet medical needs or to	
	improve covered needs	
Signal detection		

\* European Medicines Agency (EMA)

5

\*\* European Network of Health Technology Asessment Bodies (EUnetHTA)

## There are increasing requirements on evidence across product life cycle



## Studies Support In Mature Phase

#### NSCLC: 1<sup>st</sup> line treatment pattern and gene aberration test status

 BMC Cancer (2017) 17:462, CSCO 2016 podium poster, ESMO 2016 poster

#### Value of PAP (Patient Assistant Program)

- Economic model used trail data (ClinicoEconomics and Outcomes Research 2017:9 99–106)
- Economic model with real world PAP data (ISPOR Int'l 2017, Journal of Medical Economics: DOI: 10.1080/13696998.2017.1373654 )

#### Budget Impact Analysis

(ISPOR Asia 2016, poster)

### Thank you!

